{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:37:55Z","timestamp":1793241475089,"version":"4.5.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Therapeutic drug monitoring is highly recommended for children and adolescents treated with neurotropic\/psychotropic drugs. For interpretation of therapeutic drug monitoring results, drug concentrations (C\/D) expected in a \u201cnormal\u201d population are helpful to identify pharmacokinetic abnormalities or nonadherence. Using dose-related concentration (DRC) factors obtained from pharmacokinetic data, C\/D ranges expected under steady state can be easily calculated by multiplication of DRC by the daily dose. DRC factors, however, are defined only for adults so far. Therefore, it was the aim of this study to estimate DRC factors for children and adolescents and compare them with those of adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>To obtain pharmacokinetic data (apparent total clearance of drugs from plasma after oral administration, elimination half-life, area under the curve, and minimum serum drug concentration) from children and adolescents treated with psychotropic drugs, a systematic review of published literature was performed, and the pharmaceutical companies that market these drugs were contacted. Available information was used for the calculation of DRC factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Fourteen of 26 drugs had similar DRC factors to those reported for adults; 8 and 4 had higher and lower factors, respectively. The antidepressants citalopram, clomipramine, fluvoxamine, and imipramine and the antipsychotics haloperidol and olanzapine showed higher DRC factors than those calculated for adults. The DRC factors of amphetamine and methylphenidate were higher in children (6\u201312 years) but not in adolescents (13\u201317 years). On the contrary, the antipsychotic quetiapine and the mood-stabilizing antiepileptics lamotrigine, oxcarbazepine, and topiramate showed lower DRC factors than those calculated for adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>It was concluded that concentrations of neuroactive\/psychoactive drugs to be expected in blood for a given dose may differ between adults and children or adolescents, most probably owing to age-dependent differences in the elimination of these drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000685","type":"journal-article","created":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T08:10:02Z","timestamp":1565079002000},"page":"315-324","source":"Crossref","is-referenced-by-count":22,"title":["Dose-Related Concentrations of Neuroactive\/Psychoactive Drugs Expected in Blood of Children and Adolescents"],"prefix":"10.1097","volume":"42","author":[{"given":"Stefanie","family":"Fekete","sequence":"first","affiliation":[{"name":"Department Child and Adolescent Psychiatry, University Hospital of W\u00fcrzburg, W\u00fcrzburg ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Medical Center of Mainz, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Gerlach","sequence":"additional","affiliation":[{"name":"Department Child and Adolescent Psychiatry, University Hospital of W\u00fcrzburg, W\u00fcrzburg ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1055\/s-0031-1286291","article-title":"Therapeutic drug monitoring in children and adolescent psychiatry","volume":"44","author":"Egberts","year":"2011","journal-title":"Pharmacopsychiatry."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology\u2014drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/00004714-200208000-00012","article-title":"Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting","volume":"22","author":"Reis","year":"2002","journal-title":"J Clin Psychopharmacol."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1097\/00004583-199511000-00012","article-title":"Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents","volume":"34","author":"Leonard","year":"1995","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s40262-014-0149-y","article-title":"Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder","volume":"53","author":"Lobo","year":"2014","journal-title":"Clin Pharmacokinet."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1089\/cap.2018.0160","article-title":"CYP2C19-Guided escitalopram and sertraline dosing in pediatric patients: a pharmacokinetic modeling study","volume":"29","author":"Strawn","year":"2019","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/00004714-200212000-00006","article-title":"Fluoxetine pharmacokinetics in pediatric patients","volume":"22","author":"Wilens","year":"2002","journal-title":"J Clin Psychopharmacol."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1097\/01.chi.0000143546.28821.11","article-title":"Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents","volume":"43","author":"Labellarte","year":"2004","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00007691-198412000-00010","article-title":"Monitoring of serum levels of imipramine and desipramine and individualization of dose in enuretic children","volume":"6","author":"de Gatta","year":"1984","journal-title":"Ther Drug Monit."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/sj.npp.1300960","article-title":"Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder","volume":"31","author":"Findling","year":"2006","journal-title":"Neuropsychopharmacology."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/00004583-200209000-00003","article-title":"Sertraline pharmacokinetics and dynamics in adolescents","volume":"41","author":"Axelson","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1089\/cap.2008.0111","article-title":"An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder","volume":"19","author":"Findling","year":"2009","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004714-200302000-00012","article-title":"Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia","volume":"23","author":"Frazier","year":"2003","journal-title":"J Clin Psychopharmacol."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00007691-197901000-00004","article-title":"Haloperidol plasma level monitoring in pediatric patients","volume":"1","author":"Morselli","year":"1979","journal-title":"Ther Drug Monit."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00004714-200004000-00015","article-title":"Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia","volume":"20","author":"Grothe","year":"2000","journal-title":"J Clin Psychopharmacol."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/cap.2007.0084","article-title":"Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders","volume":"18","author":"Winter","year":"2008","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/FTD.0b013e318261c240","article-title":"Population pharmacokinetic modelling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents","volume":"34","author":"Sherwin","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/01.chi.0000215347.93902.3e","article-title":"Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents","volume":"45","author":"Sallee","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40262-016-0430-3","article-title":"Lithium in paediatric patients with bipolar disorder: implications for selection of dosage regimens via population pharmacokinetics\/pharmacodynamics","volume":"56","author":"Landersdorfer","year":"2017","journal-title":"Clin Pharmacokinet."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/0920-1211(89)90060-0","article-title":"Factors influencing serum levels of carbamazepine and carbamazepine-10,11-epoxide in children","volume":"4","author":"Altafullah","year":"1989","journal-title":"Epilepsy Res."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00007691-199704000-00003","article-title":"Carbamazepine population pharmacokinetics in children: mixed-effect models","volume":"19","author":"Iribanegaray","year":"1997","journal-title":"Ther Drug Monit."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1592\/phco.19.6.437.31052","article-title":"Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs","volume":"19","author":"Chen","year":"1999","journal-title":"Pharmacotherapy."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FTD.0b013e31825ee389","article-title":"Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication","volume":"34","author":"Landmark","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1111\/bcp.13392","article-title":"Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children","volume":"83","author":"Rodrigues","year":"2017","journal-title":"Br J Clin Pharmacol."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00003088-200544040-00005","article-title":"Topiramate pharmacokinetics in children and adults with epilepsy. A case-matched comparison based on therapeutic drug monitoring data","volume":"44","author":"Battino","year":"2005","journal-title":"Clin Pharmacokinet."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00228-018-2444-2","article-title":"A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy","volume":"74","author":"Rodrigues","year":"2018","journal-title":"Eur J Clin Pharmacol."},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/104454603321666199","article-title":"Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder","volume":"13","author":"Witcher","year":"2003","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clinthera.2010.02.011","article-title":"Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit\/hyperactivity disorder: a single-dose, randomized, open-label, crossover study","volume":"32","author":"Boellner","year":"2010","journal-title":"Clin Ther."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40262-015-0245-7","article-title":"Population pharmacokinetic modeling of guanfacine in pediatric patients","volume":"54","author":"Knebel","year":"2015","journal-title":"Clin Pharmacokinet."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/cap.2007.0043","article-title":"Pharmacokinetics of methylphenidate in preschoolers with attention-deficit\/hyperactivity disorder","volume":"17","author":"Wigal","year":"2007","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"R35-20230814","first-page":"25","article-title":"Antipsychotic prescription in children and adolescents. An analysis of data from a German statutory health insurance company from 2005 to 2012","volume":"111","author":"Bachmann","year":"2014","journal-title":"Dtsch \u00c4rztebl Int."},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40262-013-0065-6","article-title":"The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years","volume":"52","author":"Edginton","year":"2013","journal-title":"Clin Pharmacokinet."},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1542\/peds.2007-1529","article-title":"Improving pediatric dosing through pediatric initiatives: what we have learned","volume":"121","author":"Rodriguez","year":"2008","journal-title":"Pediatrics."},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0887-8994(99)00011-9","article-title":"A study of topiramate pharmacokinetics and tolerability in children with epilepsy","volume":"20","author":"Rosenfeld","year":"1999","journal-title":"Pediatr Neurol."},{"key":"R39-20230814","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1055\/s-0043-109695","article-title":"Relationship between daily dose, serum concentration, and clinical response to quetiapine in children and adolescents with psychotic and mood disorders","volume":"50","author":"Albantakis","year":"2017","journal-title":"Pharmacopsychiatry."},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1517\/17425255.1.3.447","article-title":"Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations","volume":"1","author":"Benedetti","year":"2005","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R41-20230814","doi-asserted-by":"crossref","first-page":"A5","DOI":"10.1055\/s-0034-1386831","article-title":"Therapeutic drug monitoring of fluvoxamine in children and adolescents","volume":"47","author":"Biener","year":"2014","journal-title":"Pharmacopsychiatry."},{"key":"R42-20230814","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/FTD.0000000000000398","article-title":"Therapeutic drug monitoring of children and adolescents under pharmacotherapy with olanzapine in daily clinical practice","volume":"39","author":"Fekete","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R43-20230814","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1089\/cap.2006.0045","article-title":"Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents","volume":"17","author":"Aichhorn","year":"2007","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"R44-20230814","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/01.ftd.0000249950.75462.7f","article-title":"Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication","volume":"28","author":"Theisen","year":"2006","journal-title":"Ther Drug Monit."},{"key":"R46-20230814","first-page":"23","article-title":"High Rate of Non-Eligibility: methodological factors impacting on recruitment for a multicentre, double-blind study of paediatric patients with major depressive disorder","volume":"46","author":"Bliznak","year":"2013","journal-title":"Pharmacopsychiatry."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000685","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T18:37:59Z","timestamp":1692038279000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000685","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}